CYCS and myocardial ischemia: In contrast, another report indicates that inhibition of chymotrypsin-like activity of the proteasome by Ixazomib prevents mitochondrial dysfunction during myocardial ischemia by blocking the release of cytochrome c and significantly preserving mitofusin-2 integrity [72].